Hot Features
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of ... Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -5.25 | -25.6097560976 | 20.5 | 20.5 | 15.25 | 2847635 | 17.46191038 | DE |
| 4 | -7.75 | -33.6956521739 | 23 | 23 | 15.25 | 1575945 | 19.14914293 | DE |
| 12 | 3.25 | 27.0833333333 | 12 | 29.5 | 12 | 2364656 | 19.33021863 | DE |
| 26 | 5.35 | 54.0404040404 | 9.9 | 29.5 | 9.9 | 1861730 | 16.48123227 | DE |
| 52 | 5.75 | 60.5263157895 | 9.5 | 29.5 | 7.9 | 1422685 | 14.14109208 | DE |
| 156 | 2 | 15.0943396226 | 13.25 | 29.5 | 7.25 | 982874 | 13.03508539 | DE |
| 260 | -6 | -28.2352941176 | 21.25 | 29.5 | 7.25 | 927502 | 14.91154796 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.